Talaporfin

Excerpt

Talaporfin [ME 2906, taporfin, LS 11, mono-L-aspartyl chlorin e6, NPE 6, NP e6] is a photosensitiser for use in photodynamic therapy, and consists of chlorin e6 in chlorophyll and L-aspartic acid.¹ It was developed by Nippon Petrochemicals and is licensed to Meiji Seika with exclusive marketing rights for Japan and South East Asia. Talaporfin is injected into tumours and other target tissues where it accumulates. It is activated with light emitting diodes (LEDs) rather than with laser light as with other photosensitisers. Talaporfin has completed phase I clinical trials in the US for the treatment of superficial malignant tumours and is undergoing phase II trials in Japan for the treatment of various cancers. Meiji Seika has submitted an NDA to the Japanese authorities for marketing approval of talaporfin in patients with early-stage lung cancer.

…